Change of address for BLA submissions
As of Oct. 4, all therapeutic biologic submissions excluding 21 CFR 600.80 postmarketing adverse experience reports; advertising and promotional labeling; and 21 CFR 600.14 biological product deviation reports should be sent to CDER Therapeutic Biological Products Document Room, Center for Drug Evaluation and Research, Food and Drug Administration, 12229 Wilkins Ave., Rockville, MD 20852. FDA hopes to continue its normal pace of review, but "I do anticipate that it might slow things down a little bit," CDER Office of Compliance Therapeutics Facilities Review Branch Facility Reviewer Carolyn Renshaw said during the PDA/FDA Regulatory Conference in Washington, D.C. Sept. 22. "There is going to be a transition period. I do believe it will be difficult mailing and getting everything on time, which was difficult to begin with"...
You may also be interested in...
Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. In any event, NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.
Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions
Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.
I.V. Korsuva now has an August FDA action date, which partner Vifor would commercialize in the ESRD dialysis setting while Cara works toward a broad anti-pruritus label for its oral tablet formulation.